Trials / Sponsors / Beijing Biotech
Beijing Biotech
Industry · 16 registered clinical trials — 16 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS, Lupus Nephritis | Phase 1 / Phase 2 | 2026-03-02 |
| Recruiting | Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL, Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia | Phase 1 / Phase 2 | 2026-03-02 |
| Recruiting | Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma Malignant Pleural Mesotheliomas | Phase 1 / Phase 2 | 2026-03-02 |
| Recruiting | Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC Advanced Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer | Phase 1 / Phase 2 | 2026-03-02 |
| Recruiting | Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma Relapsed Neuroblastoma, Refractory Neuroblastoma, High-Risk Neuroblastoma | Phase 1 / Phase 2 | 2026-03-02 |
| Recruiting | PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors Advanced or Metastatic Solid Tumors | Phase 1 / Phase 2 | 2026-03-02 |
| Recruiting | Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma | Phase 1 | 2026-03-02 |
| Recruiting | Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors Advanced Unresectable, Metastatic | Phase 1 / Phase 2 | 2026-03-02 |
| Recruiting | Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma | Phase 1 / Phase 2 | 2026-02-04 |
| Recruiting | Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC) | Phase 1 / Phase 2 | 2026-02-02 |
| Recruiting | Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC Breast Cancer (Advanced/Metastatic), HER2-positive Breast Cancer, Triple-negative Breast Cancer | Phase 1 / Phase 2 | 2026-02-02 |
| Recruiting | Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma Glioblastoma, High-grade Glioma, Malignant Glioma | Phase 1 | 2026-02-02 |
| Recruiting | Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC Non-Small Cell Lung Cancer, Advanced/Metastatic NSCLC | Phase 1 / Phase 2 | 2026-02-02 |
| Recruiting | Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC, SCLC, Extensive Stage | Phase 1 / Phase 2 | 2026-02-02 |
| Recruiting | Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced or Metastatic Disease | Phase 1 / Phase 2 | 2026-02-02 |
| Recruiting | Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer Colorectal Cancer Metastatic, Adenocarcinoma of Colon | Phase 1 / Phase 2 | 2026-02-01 |